These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 37751024

  • 1. Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.
    Lafayette RA, Charu V.
    Adv Ther; 2023 Dec; 40(12):5557-5566. PubMed ID: 37751024
    [Abstract] [Full Text] [Related]

  • 2. C3 glomerulopathy and current dilemmas.
    Ito N, Ohashi R, Nagata M.
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [Abstract] [Full Text] [Related]

  • 3. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
    Al-Ghaithi B, Chanchlani R, Riedl M, Thorner P, Licht C.
    Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
    [Abstract] [Full Text] [Related]

  • 4. C3 Glomerulopathy.
    Riedl M, Thorner P, Licht C.
    Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
    [Abstract] [Full Text] [Related]

  • 5. C3 Glomerulopathy: Pathogenesis and Treatment.
    Ahmad SB, Bomback AS.
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242
    [Abstract] [Full Text] [Related]

  • 6. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
    Hawfield A, Iskandar SS, Smith RJ.
    Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
    [Abstract] [Full Text] [Related]

  • 7. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.
    Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G.
    Mol Immunol; 2016 Mar; 71():131-142. PubMed ID: 26895476
    [Abstract] [Full Text] [Related]

  • 8. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
    Chen YY, Han SS, Cao Y, Yu XJ, Zhu L, Luo JC, Song WC, Yu F, Mao YH, Zhao MH.
    Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
    [Abstract] [Full Text] [Related]

  • 9. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ.
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [Abstract] [Full Text] [Related]

  • 10. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
    Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez E, de la Cerda F, Pérez de José A, López I, Fernández L, Pérez Gómez V, Ávila A, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illescas ML, Calvo C, Oviedo V, Da Silva I, Goicoechea de Jorge E, Caravaca F, Praga M, C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN).
    Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
    [Abstract] [Full Text] [Related]

  • 11. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ.
    Clin J Am Soc Nephrol; 2014 Nov 07; 9(11):1876-82. PubMed ID: 25341722
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
    Michels MAHM, van de Kar NCAJ, van Kraaij SAW, Sarlea SA, Gracchi V, Engels FAPT, Dorresteijn EM, van der Deure J, Duineveld C, Wetzels JFM, van den Heuvel LPWJ, Volokhina EB.
    Front Immunol; 2021 Nov 07; 12():715704. PubMed ID: 34456924
    [Abstract] [Full Text] [Related]

  • 15. Complement inhibition in C3 glomerulopathy.
    Nester CM, Smith RJ.
    Semin Immunol; 2016 Jun 07; 28(3):241-9. PubMed ID: 27402056
    [Abstract] [Full Text] [Related]

  • 16. C3 glomerulonephritis with a severe crescentic phenotype.
    Ravindran A, Fervenza FC, Smith RJH, Sethi S.
    Pediatr Nephrol; 2017 Sep 07; 32(9):1625-1633. PubMed ID: 28593446
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of C4d as a diagnostic tool to classify membranoproliferative glomerulonephritis.
    Gupta N, Wakefield DN, Clapp WL, Garin EH.
    Nefrologia; 2017 Sep 07; 37(1):78-86. PubMed ID: 27595516
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The C3 conundrum.
    Lean M, Chacko B.
    Intern Med J; 2023 Jun 07; 53(6):1065-1069. PubMed ID: 37278101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.